newsfilter
← Latest News
GlobeNewswire·

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing